PharmExec Direct:
Having trouble viewing this e-mail? Click here.
PharmExec Direct | From the editors of Pharmaceutical Executive Visit the PharmExec website
 
Send Us Some Feedback
| Advertise With Us | Visit PharmExec.com | PRINT SUBSCRIBE | DIGITAL SUBSCRIBE
 March 19, 2015 | ISSUE NUMBER 392 VOL 4

Top Story
Biosimilars in the US: Five Key Commercial Considerations
The landmark approval by the FDA of Novartis’ Zarxio means biosimilars have finally arrived on U.S. shores and companies entering this blossoming market should now be turning even greater attention to commercialization, says Rohit Sood. Here, he outlines five critical factors for companies entering the biosimilars market ...Read more

learn more about how to leverage Data and Analytics to enhance Copay Program Performance with this White Paper and Case Study: Read more

Strategy
Partnering in a Volume-to-Value Transformational Environment
In the shift from volume to value as the underlying driver in health care, pharma has only scratched the surface of possibility for new and non-traditional arrangements with a broader variety of partners with healthcare interests, writes Pharm Exec Editorial Advisory Board member Cliff Kalb ...Read more

Private sector consensus on how to deliver value and innovation in healthcare? Read this report to learn what senior execs from leading healthcare companies are saying.

Regulatory
Pharma Disclosures Draw Securities and Exchange Commission Scrutiny
The Securities and Exchange Commission (SEC) is focusing more on the accuracy and timeliness of biopharma company financial filings, particularly those related to regulatory actions involving FDA, writes Jill Wechsler ...Read more

Leadership
Deadline for Nomination: Pharm Exec’s 2015 Emerging Pharma Leaders
Pharm Exec is looking for the fresh faces of pharma leadership, and we'd like your input! Tell us who you think should be included as one of Pharmaceutical Executive's 2015 Emerging Pharma Leaders. Read more for details of how to nominate a colleague — or yourself. The deadline for this year’s entries is April 15 ...Read more

Marketing
Patients, Physicians, and Payers… How Can Pharma Do It All?
The word ‘centric’ by definition means one, as in focused on a single entity. Yet, in today’s life sciences industry, companies are customer-centric and patient-centric and physician-centric – all combined. It’s counterintuitive, if not overwhelming, write Lisa Barbadora ...Read more

//The International Society for CNS Drug Development (ISCDD) awarded Antony Loebel, M.D., Executive Vice President and Chief Medical Officer of Sunovion (Marlborough, MA), the 2015 ISCDD Award for Leadership at its 13th Annual Meeting.//IXenon Pharmaceuticals (Burnaby, British Columbia, Cananda) announced that Richard H. Scheller, Ph.D., has been appointed to its Board of Directors.//Crown Bioscience (Santa Clara, CA) appointed Sebastian Dempe as Business Development Manager for central Europe.//Inovio Pharmaceuticals (Plymouth Meeting, PA) appointed Scott M. White, M.D. as Vice President, Clinical Development – Infectious Diseases.//

March 24–24: eyeforpharma Barcelona
Barcelona, Spain


April 15–16: Global Transparency Reporting Conference
London, UK


May 14–15: iPharma 2015
New York, NY


 
Follow Pharm Exec on Twitter
Follow Pharm Exec on Linkedin

Quick Links

Jack Whelan: A Patient Perspective on Patient Engagement

Brand Strategies and the Growing Influence of IDNs

Will FDA Fixes Spur Innovation?

Pharm Exec eBooks Available as Apps